10-K - Femasys Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

A year of accelerating commercial traction offset by acute liquidity constraints—revenue surged 41% driven by FemBloc's European launch, yet the company faces a going concern warning with cash runway extending only to Q3 2026.

Key Takeaways

1Operating cash burn improved slightly to $18.7M from $19.4M prior year despite increased inventory investment.

2FDA approved IDE supplement for final phase of FemBloc pivotal trial in November 2025, with enrollment initiated March 2026.

Key Financial Metrics

EPS

$-0.47

44.7%

Revenue

$2.3M

40.8%

Net Income

-$18.6M

1.0%

Gross Margin

62.0%

Gross Profit

$1.4M

31.1%

free cash flow

-$19.2M

Operating Income

-$17.6M

1.1%

operating margin

-767.0%